Sanofi: Leukemia trials
The registry lists 12 Leukemia studies with Sanofi as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 3Phase 2 9Phase 3 1Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic SyndromeTerminatedNCT03594955Phase 1/2Results posted
- Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaTerminatedNCT02999633Phase 2Results posted
- Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00328198Phase 2Results posted
- A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.CompletedNCT00315705Phase 1/2Results posted
- Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis SyndromeCompletedNCT00230178Phase 3Results posted
- Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or LymphomaCompletedNCT00631579Phase 2
- Rasburicase for HyperuricemiaCompletedNCT00290992Phase 2
- Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor MalignancyCompletedNCT00230217Phase 4
- Clofarabine in Adult Patients With Advanced Solid TumorsCompletedNCT00125840Phase 1
- Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) PatientsCompletedNCT00042354Phase 2
- Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00042341Phase 2
- Aminopterin in Treating Patients With Refractory LeukemiaCompletedNCT00003305Phase 2